Novartis Plans 140 Billion Won RLT Hub in Korea
Novartis will invest about 140 billion won to build Korea’s domestic radioligand therapy ecosystem, including local manufacturing, advanced cold-chain logistics, and a plan to train RLT specialists while expanding treatment sites from 10 to 30 hospitals. In partnership with the Ministry of Health and Welfare, the move aims to boost Korea’s RLT research, development, and manufacturing capabilities and improve access for cancer patients.